Tools / Drug approvals and letters / Drugs Lisdexamfetamine Dimesylate Sold as Vyvanse, Arynta. Every FDA application for this active ingredient: 3 branded and 22 generic.
As of Nov 15, 2026, FDA lists 25 applications for Lisdexamfetamine Dimesylate (sold as Vyvanse, Arynta), first approved Feb 23, 2007, with 10 new uses approved and 0 published complete response letters.
First approved : Feb 23, 2007 Applications : 25 New uses approved : 10 Complete response letters : 0 Medicare spending, 2025 : $107M Shortage : Current
Medicare Spending CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name What Pharmacies Pay Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change VYVANSE 10 MG CAPSULE: $12.35 per unit Brand · 0% in a year VYVANSE 10 MG CHEWABLE TABLET: $12.35 per unit Brand · +0% in a year VYVANSE 20 MG CAPSULE: $12.35 per unit Brand · 0% in a year VYVANSE 20 MG CHEWABLE TABLET: $12.34 per unit Brand · 0% in a year VYVANSE 30 MG CAPSULE: $12.34 per unit Brand · 0% in a year VYVANSE 30 MG CHEWABLE TABLET: $12.35 per unit Brand · 0% in a year VYVANSE 40 MG CAPSULE: $12.35 per unit Brand · 0% in a year VYVANSE 40 MG CHEWABLE TABLET: $12.35 per unit Brand · 0% in a year VYVANSE 50 MG CAPSULE: $12.35 per unit Brand · 0% in a year VYVANSE 50 MG CHEWABLE TABLET: $12.35 per unit Brand · +0% in a year VYVANSE 60 MG CAPSULE: $12.36 per unit Brand · 0% in a year VYVANSE 60 MG CHEWABLE TABLET: $12.36 per unit Brand · +0% in a year
Shortages FDA's drug shortage list, as of Nov 13, 2026 Clinical Trials 6 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all Study Phase Status Posted Lisdexamfetamine For the Treatment of Conduct Disorder in Children Conduct Disorder · Orygen Phase 2 Not yet recruiting Nov 6, 2026 Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder Obesity and Overweight, Binge Eating Disorder · Johns Hopkins University Phase 2 Recruiting Feb 26, 2025 Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder Methamphetamine Abuse, Methamphetamine-dependence · Centre hospitalier de l'Université de Montréal (CHUM) Phase 2 Recruiting Jan 23, 2025 Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes Attention Deficit Disorder with Hyperactivity, Diabetes Mellitus, Type 1 · Medical University of Lodz Phase 2 Recruiting Jul 24, 2023 Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users Methamphetamine Abuse, Methamphetamine-dependence · Centre hospitalier de l'Université de Montréal (CHUM) Phase 2 Recruiting May 11, 2023 Stimulant Effects on Disruptive Behavior Attention Deficit Hyperactivity Disorder, Problem Behavior · Matthew J O'Brien, PhD, BCBA-D Phase 4 Recruiting Feb 5, 2018
Applications NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history Approved Application Sponsor Supplements Marketing Feb 23, 2007 Vyvanse NDA 21977 · New molecular entity Takeda Pharms USA43 Marketed Jan 28, 2017 Vyvanse NDA 208510 · New dosage form Takeda Pharms USA8 Marketed Aug 25, 2023 Lisdexamfetamine Dimesylate ANDA 202802 Actavis Elizabeth1 Marketed Aug 25, 2023 Lisdexamfetamine Dimesylate ANDA 202827 Hikma4 Marketed Aug 25, 2023 Lisdexamfetamine Dimesylate ANDA 202830 Amneal1 Marketed Aug 25, 2023 Lisdexamfetamine Dimesylate ANDA 202835 Mylan0 Marketed Aug 25, 2023 Lisdexamfetamine Dimesylate ANDA 211840 Specgx LLC1 Marketed Aug 25, 2023 Lisdexamfetamine Dimesylate ANDA 214134 Sun Pharm Inds Inc1 Marketed Aug 25, 2023 Lisdexamfetamine Dimesylate ANDA 214484 Sun Pharm Inds Inc1 Marketed Aug 25, 2023 Lisdexamfetamine Dimesylate ANDA 214547 Norwich3 Marketed Aug 25, 2023 Lisdexamfetamine Dimesylate ANDA 215330 Rhodes Pharms0 Marketed Aug 25, 2023 Lisdexamfetamine Dimesylate ANDA 215415 Teva Pharms0 Marketed Aug 25, 2023 Lisdexamfetamine Dimesylate ANDA 215802 Lannett Co Inc3 Marketed Aug 25, 2023 Lisdexamfetamine Dimesylate ANDA 216266 Prinston3 Marketed Aug 25, 2023 Lisdexamfetamine Dimesylate ANDA 216944 Apotex3 Marketed Aug 25, 2023 Lisdexamfetamine Dimesylate ANDA 217068 Ascent Pharms Inc3 Marketed Aug 25, 2023 Lisdexamfetamine Dimesylate ANDA 217194 Alkem Labs Ltd1 Marketed Aug 25, 2023 Lisdexamfetamine Dimesylate ANDA 217442 Ascent Pharms Inc3 Marketed Feb 2, 2024 Lisdexamfetamine Dimesylate ANDA 218306 Msn0 Marketed Jul 26, 2024 Lisdexamfetamine Dimesylate ANDA 202836 Sandoz1 Marketed Nov 15, 2024 Lisdexamfetamine Dimesylate ANDA 218604 Elite Labs Inc0 Marketed Dec 16, 2024 Lisdexamfetamine Dimesylate ANDA 219258 Granules2 Marketed Dec 17, 2024 Lisdexamfetamine Dimesylate ANDA 218850 Specgx LLC0 Marketed Jan 29, 2025 Lisdexamfetamine Dimesylate ANDA 218987 Granules2 Marketed Jun 16, 2025 Arynta NDA 219847 · New dosage form Azurity1 Marketed
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA